Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd Monotherapy in Advanced Solid Tumors (China I/II)
CTR20221708Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), gastric cancer (GC), esophagogastric junction cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2022; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20221708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221708.